Hosted on MSN1mon
Glenmark Pharmaceuticals introduces Latanoprost Ophthalmic Solution in the U.S.
The Xalatan Ophthalmic Solution, 0.005% market achieved annual sales of approximately $113.5 million, according to IQVIA sales data for the 12-month period that ended in December 2024.
Hosted on MSN1mon
Glenmark Expands Ophthalmic Portfolio in the US with Latanoprost Launch
Glenmark Pharmaceuticals (NSE:GLEN) Inc., USA (Glenmark) has announced the launch of Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), further strengthening its presence in the ophthalmic segment.
Medscape8y
Effect of Switching From Latanoprost to Bimatoprost in POAG
Purpose: We investigated the intraocular pressure (IOP) variations after switching from 0.005% latanoprost to 0.01% bimatoprost in open-angle glaucoma patients who experienced IOP elevation during ...
pharmaphorum2y
Nicox glaucoma drug works, but not as well as hoped
On the plus side, the Mont Blanc trial of the drug showed that it was as effective in treating the eye disease as prostaglandin analogue latanoprost 0.005%, a standard therapy for glaucoma ...
Yahoo Finance6d
ROCKLATAN/ROCLANDA Strengthens Market Position with Robust Sales and Patient Outcomes | DelveInsight
ROCKLATAN/ROCLANDA (netarsudil and latanoprost ophthalmic solution) 0.02% and 0.005% is a prescription drug used to lower ...